Painless myocardial ischemia in patients with rheumatoid arthritis
- Authors: Striuk RI1, Leonova EA2, Tedikova NS2, Gosteva OV2
-
Affiliations:
- Московский государственный медико-стоматологический университет
- МУЗ Городская больница № 4, Тольятти
- Issue: Vol 80, No 5 (2008)
- Pages: 16-20
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/30156
- ID: 30156
Cite item
Full Text
Abstract
Aim. To ascertain prevalence and prognostic implication of painless myocardial ischemia (PMI) in patients with rheumatoid arthritis (RA) in respect to stage, severity of inflammation and characteristics of the lipid profile. Material and methods. A 24-h Hotter ECG monitoring, tests for total cholesterol, triglycerides and lipid spectrum were made in 94 patients with a documented rheumatoid arthritis (RA) aged 36-68 years (mean age 54.8 ± 8.0years, 13 males and 81 females) admitted to Toliatti municipal hospital N 4. The control group consisted of 20 patients with a history of myocardial infarction. Forty RA patients were followed up for mean 1.1 year after basic therapy. Results. Hotter ECG monitoring detected ischemic depression of ST segment in 46 (48.9%) RA patients and 9 (45%) patients with coronary heart disease. RA patients with PMI had changes in the lipid profile in the direction of elevation of atherogenic components and C-reactive protein characterizing severity of inflammation. Basic treatment of RA eliminated PMI symptoms in some patients. This correlated with attenuation of inflammation. Some RA patients had first symptoms of PMI, on the average, on follow-up year 1.1 and higher plasmic atherogenicity. Conclusion. About 50% RA patients free of clinical symptoms of coronary heart disease had PMI caused by both coronarogenic (atherosclerotic) factors and non-coronarogenic (immunocomplex inflammation) mechanisms.
Full Text
##article.viewOnOriginalSite##About the authors
R I Striuk
Московский государственный медико-стоматологический университет
E A Leonova
МУЗ Городская больница № 4, Тольятти
N S Tedikova
МУЗ Городская больница № 4, Тольятти
O V Gosteva
МУЗ Городская больница № 4, Тольятти
References
- Насонов Е. Л. Проблема атеротромбоза в ревматологии. Вестн. РАМН 2003; 7: 6-10.
- Грацианский Н. А. Статины как противовоспалительные средства. Кардиология 2001; 12: 14-25.
- Кондратьев В. В., Бочкарева Е. В., Кокурина Е. В. Безболевая ишемия миокарда. Современное состояние проблемы и клинически значимые аспекты ее развития. Кардиология 1997; 2: 90-97.
- Алехин М. Н., Божьев А. М., Морозова Ю. А. и др. Возможности стресс-эхокардиографии с тредмилом в оценке безболевой ишемии миокарда у больных ишемической болезнью сердца. Кардиология 2000; 11: 13-16.
- Насонов Е. Л., Чичасова Н. В., Имаметдинова Г. Р. Методы оценки поражения суставов, активности заболевания и функционального состояния больных ревматоидным артритом: Метод. пособие для врачей. М., 2001.
- Nissen S. Е., Tuzcu Е. М., Schoenhagen P. et al. REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atheroscltrosis: a randomized controlled trial. JAMA 2004; 291 (9): 1071-1080.
- Сусеков А. В. Эффект статинов на нелипидные маркеры ишемической болезни сердца: С-реактивный белок и фибриноген. Атмосфера. Кардиология 2003; 4: 21-24.
- Ross R. Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 1999; 340: 115-126.
- Ridker P. M. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107: 363-369.
- Шальнова С. А., Леев А. Д. Характеристика пациентов высокого риска. Результаты эпидемиологической части научно-образовательной программы ОСКАР. Кардиоваск. тер. и профилакт. 2006; 5: 58-63.
- Sattar N., McCarey D. W., Capell H., McInnes I. B. Explaining how "highgrade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003; 108 (24): 2957-2963.
- Boers V., Nurmohamed M. T., Doelman C. L. et al. Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis. 2003; 62 (9): 842-845.
- Goodson N. J., Wiles N. J., Lunt M. et al. Mortality in early seropositive polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthr. and Rheum. 2002; 46: 2010-2019.
- Wallberg-Jonsson S., Ohman M. L., Dahlqvist S. R. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J. Rheumatol. 1997; 24 (3): 445-451.
- Book C., Saxne N., Jacobsson L. T. Prediction of mortality in rheumatoid arthritis based on disease activity markers. J. Rheumatol. 2005; 32 (3): 430-434.
- Gabriel S. E., Growson C. S., Kremers H. M. et al. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthr. and Rheum. 2003; 48 (1): 54-58.
- Munro R., Morrison E., McDonald A. G. et al. Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis. Ann. Rheum. Dis. 1997; 56 (6): 374-377.
![](/img/style/loading.gif)